Overview

Study of INCB086550 in Select Solid Tumors

Status:
Recruiting
Trial end date:
2024-02-19
Target enrollment:
Participant gender:
Summary
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation